Gene Biotherapeutics Inc Quick Ratio (CRXM) starting from the fourth quarter 2020 to fourth quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gene Biotherapeutics Inc   (CRXM)

Gene Biotherapeutics Inc 's Quick Ratio

CRXM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2020, Quick Ratio fell to 0.08 below Gene Biotherapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 129 other companies have achieved higher Quick Ratio than Gene Biotherapeutics Inc in fourth quarter 2020. While Quick Ratio total ranking in the fourth quarter 2020 has deteriorated compared to the prior quarter from 4097 to 4335.

Explain Quick Ratio?
How much Cash & cash equivalents CRXM´s has?
What are CRXM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CRXM Quick Ratio (Dec 31 2020)
Q4		 (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4
Y / Y Current Liabilities Change 5.55 % - - - -4.08 %
Y / Y Cash & cash equivalent Change 96406.75 % - - - -99.51 %
Quick Ratio MRQ 0.08 0.16 0.28 0 0
CRXM's Total Ranking # 4335 # 4097 # 3500 # 5215 # 5275
Seq. Current Liabilities Change 2.04 % 3.84 % -3.22 % 2.93 % -
Seq. Cash & cash equivalent Change -50.61 % -40.45 % 44755.54 % 631.5 % -



Quick Ratio fourth quarter 2020 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 130
Healthcare Sector # 905
Overall Market # 4335


Quick Ratio Statistics
High Average Low
0.42 0.11 0
(Sep 30 2016)   (Dec 31 2019)




Financial Statements
Gene Biotherapeutics Inc 's Current Liabilities $ 5 Millions Visit CRXM's Balance sheet
Gene Biotherapeutics Inc 's Cash & cash equivalent $ 0 Millions Visit CRXM's Balance sheet
Source of CRXM's Sales Visit CRXM's Sales by Geography


Cumulative Gene Biotherapeutics Inc 's Quick Ratio

CRXM's Quick Ratio for the trailling 12 Months

CRXM Quick Ratio

 (Dec 31 2020)
12 Months		 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months
Y / Y Current Liabilities TTM Growth 311.53 % 289.41 % 190.2 % 94.65 % -4.08 %
Y / Y Cash & cash equivalent TTM Growth 620649.25 % 2454.65 % 1502.68 % -95.95 % -99.51 %
Quick Ratio TTM 0.13 0.11 0.09 0 0
Total Ranking TTM # 4818 # 3682 # 3968 # 4843 # 4823
Seq. Current Liabilities TTM Growth 1.37 % 34.19 % 49.09 % 102.93 % -4.08 %
Seq. Cash & cash equivalent TTM Growth 18.39 % 59.4 % 39461 % 731.5 % -99.51 %

Quick ratio ranking by company, industry and sector >> Back to CRXM Financial Strength Comparisons >> Go to Compare CRXM Quick Ratio to its Competitors

On the trailing twelve months basis CRXM Cash & cash equivalent more than doubled by 96406.75 % in Q4 2020 year on year, faster than Current Liabilities, this led to increase in in Gene Biotherapeutics Inc 's Quick Ratio to 0.13, above CRXM average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 125 other companies have achieved higher Quick Ratio than Gene Biotherapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2020 from 3682 to 4818.

Explain Quick Ratio?
How much Cash & cash equivalents CRXM´s has?
What are CRXM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 126
Healthcare Sector # 950
Within the Market # 4818


trailing twelve months Quick Ratio Statistics
High Average Low
0.17 0.09 0.01
(Mar 31 2017)   (Jun 30 2016)




Companies with similar Quick Ratio in the quarter ending Dec 31 2020, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2020 MRQ Cash & cash equivalentDec 31 2020 MRQ Current Liabilities
Clarus Therapeutics Holdings Inc.  0.19 $ 14.438  Millions$ 76.511  Millions
Scinai Immunotherapeutics Ltd  0.15 $ 3.029  Millions$ 20.546  Millions
Xtant Medical Holdings Inc   0.09 $ 2.341  Millions$ 25.649  Millions
Gene Biotherapeutics Inc   0.08 $ 0.386  Millions$ 5.027  Millions
Qrons Inc   0.08 $ 0.058  Millions$ 0.752  Millions
Replicel Life Sciences Inc   0.03 $ 0.049  Millions$ 1.756  Millions
Mymetics Corporation  0.02 $ 1.213  Millions$ 70.857  Millions
Cannabis Global Inc.  0.02 $ 0.067  Millions$ 4.107  Millions

Date modified: 2026-09-08T15:10:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.